Drug intelligence / Profile preview

ACU234

Development stage: Preclinical
Lead developer: Acumen Pharmaceuticals
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

ACU234 is an AβO-selective antibody developed by Acumen Pharmaceuticals for the treatment of Alzheimer's disease. It is being explored as a component in fusion protein candidates, such as EBD-ACU234, which aim to enhance brain delivery through collaboration with JCR Pharmaceuticals' J-Brain Cargo technology.

Targets

Aβ oligomers (Amyloid-β oligomers)

Beyond the preview

Go deeper on ACU234.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ACU234.